Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
Status:
Completed
Trial end date:
2016-07-27
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, single center, phase 2 study with the use of the
antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell
tumors who are not cured following first or subsequent chemotherapy lines for metastatic
disease, followed by eventual surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano